| Daratumumab in Pediatric Relapsed/Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma: DELPHINUS Study T Bhatla, LE Hogan, DT Teachey, F Bautista, J Moppett, PV Puyó, ... Blood, 2024 | | 2024 |
| Impact of Genetic Ancestry on T-cell Acute Lymphoblastic Leukemia Outcomes D Teachey, H Newman, S Lee, P Pölönen, R Shraim, Y Li, H Liu, ... | | 2024 |
| The genomic basis of childhood T-lineage acute lymphoblastic leukaemia P Pölönen, D Di Giacomo, AE Seffernick, A Elsayed, S Kimura, F Benini, ... Nature, 1-10, 2024 | 1 | 2024 |
| Anti-CD7 allogeneic WU-CART-007 in patients with relapsed/refractory T-cell acute lymphoblastic leukemia/lymphoma: a phase 1/2 trial A Ghobadi, I Aldoss, S Maude, D Bhojwani, A Wayne, A Bajel, B Dholaria, ... Research Square, 2024 | | 2024 |
| Genomic Determinants of Outcome in Acute Lymphoblastic Leukemia TC Chang, W Chen, C Qu, Z Cheng, D Hedges, A Elsayed, SB Pounds, ... Journal of Clinical Oncology, JCO. 23.02238, 2024 | | 2024 |
| Blinatumomab for MRD-negative acute lymphoblastic leukemia in adults MR Litzow, Z Sun, RJ Mattison, EM Paietta, KG Roberts, Y Zhang, ... New England Journal of Medicine 391 (4), 320-333, 2024 | 5 | 2024 |
| Comparison of immunoglobulin high-throughput sequencing MRD in bone marrow and peripheral blood in pediatric B-ALL: A report from the Children's Oncology Group AALL1731. R Rau, S Gupta, JA Kairalla, C Wang, LW Lee, HM Simmons, KR Rabin, ... Journal of Clinical Oncology 42 (16_suppl), 10014-10014, 2024 | | 2024 |
| MRD at the end of induction and EFS in T-cell lymphoblastic lymphoma: Children’s Oncology Group trial AALL1231 RJ Hayashi, ML Hermiston, BL Wood, DT Teachey, M Devidas, Z Chen, ... Blood 143 (20), 2053-2058, 2024 | 1 | 2024 |
| Development of second genetically distinct T-lymphoblastic leukemia in a pediatric patient H Hultquist, A Rodriguez, JE Ferreira, A Placek, KP Miller, BL Wood, ... Pediatric blood & cancer, e31050, 2024 | | 2024 |
| A de novo germline RUNX1 variant preceding development of concurrent T-lymphoblastic leukemia and myelodysplastic syndrome CP Wang, JE Ferreira, A Placek, P Aguayo-Hiraldo, G Raca, BL Wood, ... Leukemia & Lymphoma, 1-5, 2024 | | 2024 |
| Enhanced Risk Stratification for Children and Young Adults with B-Cell Acute Lymphoblastic Leukemia: A Children’s Oncology Group Report NJ DelRocco, ML Loh, MJ Borowitz, S Gupta, KR Rabin, ... Leukemia 38 (4), 720-728, 2024 | 3 | 2024 |
| Maturational dyssynchrony in benign B-cell precursors following lymphocyte depleting chemotherapy: A potential pitfall for B-lymphoblastic leukemia minimal/measurable residual … A Placek, B Lockhart, KP Miller, GB Wertheim, SL Maude, BL Wood, ... Cytometry. Part B, Clinical cytometry 106 (2), 138-141, 2024 | 1 | 2024 |
| Quantification of measurable residual disease using duplex sequencing in adults with acute myeloid leukemia LW Dillon, J Higgins, H Nasif, M Othus, L Beppu, TH Smith, E Schmidt, ... Haematologica 109 (2), 401, 2024 | 12 | 2024 |
| Outcomes in Children, Adolescents, and Young Adults With Down Syndrome and ALL: A Report From the Children's Oncology Group KR Rabin, M Devidas, Z Chen, L Ji, J Kairalla, JK Hitzler, JJ Yang, ... Journal of Clinical Oncology 42 (2), 218-227, 2024 | 6 | 2024 |
| Prognostic significance of ETP phenotype and minimal residual disease in T-ALL: a Children’s Oncology Group study BL Wood, M Devidas, RJ Summers, Z Chen, B Asselin, KR Rabin, ... Blood 142 (24), 2069-2078, 2023 | 18 | 2023 |
| Risk-Adjusted Therapies Yield Equivalent Outcomes for Adolescents and Young Adults (AYAs) Treated for Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (T-ALL) on Children's … SI Colace, M Devidas, ZB Chen, RJ Hayashi, BL Wood, N Esiashvili, ... Blood 142, 517, 2023 | 2 | 2023 |
| Long-Term Follow up for SWOG 1318: Combination of Dasatinib, Prednisone, and Blinatumomab for Older Patients with Philadelphia-Chromosome (Ph) Positive Acute Lymphoblastic … AS Advani, AB Moseley, KM O'Dwyer, BL Wood, JH Park, MJ Wieduwilt, ... Blood 142, 1499, 2023 | 1 | 2023 |
| Real-World Performance of 2022 Revised World Health Organization (WHO) Criteria for Mixed Phenotype Acute Leukemia (MPAL) B/Myeloid Defined Only By Isolated MPO Expression (isoMPO) AE Kovach, SS Raikar, J Malvar, MJ Oberley, G Wertheim, KR Rabin, ... Blood 142, 1467, 2023 | | 2023 |
| Assessment of outcomes of consolidation therapy by number of cycles of blinatumomab received in newly diagnosed measurable residual disease negative patients with B-lineage … SM Luger, Z Sun, RJ Mattison, E Paietta, KG Roberts, Y Zhang, ... Blood 142, 2877, 2023 | 5 | 2023 |
| Next-Generation Sequencing (NGS) for Residual Disease (MRD) Monitoring in T-Lymphoblastic Leukemia (T-ALL) N Roy, ZJ Mao, C Xu, DT Teachey, ZB Chen, M Devidas, X Chen, ... Blood 142, 2976, 2023 | 1 | 2023 |
